1. |
Yang W, Lu J, Wang J, et al. Prevalence of diabetes among men and women in China[J]. N Engl J Med, 2010, 362(12): 1090-1101.
|
2. |
Mitka M. Bariatric surgery continues to show benefits for patients with diabetes[J]. JAMA, 2012, 307(18):1901-1902.
|
3. |
Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes[J]. N Engl J Med, 2012, 366(17):1567-1576.
|
4. |
郑成竹, 丁丹. 国内开展手术治疗糖尿病的原则及相关问题[J]. 中国实用外科杂志, 2010, 30(7):574-577.
|
5. |
丁丹, 郑成竹. 手术治疗肥胖症及糖尿病——在共识与争议中发展[J]. 中国实用外科杂志, 2011, 31(1):59-62.
|
6. |
Chai F, Wang Y, Zhou Y, et al. Adiponectin downregulateshyperglycemia and reduces pancreatic islet apoptosis after Roux-en-Y gastric bypass surgery[J]. Obes Surg, 2011, 21(6):768-773.
|
7. |
Umeda LM, Silva EA, Carneiro G, et al. Early improvement in glycemic control after bariatric surgery and its relationships with insulin, GLP-1, and glucagon secretion in type 2 diabetic patients[J]. Obes Surg, 2011, 21(7): 896-901.
|
8. |
Flatt PR, Bailey CJ, Green BD. Recent advances in antidiabetic drug therapies targeting the enteroinsular axis[J]. Curr Drug Metab, 2009, 10(2): 125-137.
|
9. |
Flatt PR. Effective surgical treatment of obesity may be mediated by ablation of the lipogenic gut hormone gastric inhibitory polypeptide (GIP): evidence and clinical opportunity for development of new obesity-diabetes drugs?[J]. Diab Vasc Dis Res, 2007, 4(2):151-153.
|
10. |
Pories WJ, Albrecht RJ. Etiology of typeⅡdiabetes mellitus:role of the foregut[J]. World J Surg, 2001, 25(4):527-531.
|
11. |
Aylwin S. Gastrointestinal surgery and gut hormones[J]. Curr Opin Endocrinol Diabetes, 2005, 12(1):89-98.
|
12. |
Cho YM, Kieffer TJ. New aspects of an old drug:metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser[J]. Diabetologia, 2011, 54(2):219-222.
|
13. |
Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36[J]. N Engl J Med, 2003, 349(10):941-948.
|
14. |
Moo TA, Rubino F. Gastrointestinal surgery as treatment for type 2 diabetes[J]. Curr Opin Endocrinol Diabetes Obes, 2008, 15(2):153-158.
|
15. |
童颖丹, 何剪太, 张阳德. 2型糖尿病的外科治疗[J]. 中国现代医学杂志, 2011, 21(7): 837-840.
|
16. |
Vendrell J, Broch M, Vilarrasa N, et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity[J]. Obes Res, 2004, 12(6):962-971.
|
17. |
Hindle AK, Edwards C, McCaffrey T, et al. Reactivation of adiponectin expression in obese patients after bariatric surgery[J]. Surg Endosc, 2010, 24(6):1367-1373.
|
18. |
Prospective Studies Collaboration;Whitlock G, Lewington S, et al. Body-mass index and cause-specific mortality in 900 000 adults:collaborative analyses of 57 prospective studies[J]. Lancet, 2009, 373(9669):1083-1096.
|
19. |
Hotamisligil GS. Inflammation and metabolic disorders[J].Nature, 2006, 444(7121):860-867.
|
20. |
Toghaw P, Matone A, Lenbury Y, et al. Bariatric surgery and T2DM improvement mechanisms: a mathematical model[J]. Theor Biol Med Model, 2012, 9(1):16.
|
21. |
Ferchak CV, Meneghini LF. Obesity, bariatric surgery and type 2 diabetes——a systematic review[J]. Diabetes Metab Res Rev, 2004, 20(6):438-445.
|